Daniel Normolle

Associate Professor at Biostatistics, University of Pittsburgh-Bradford0 Followers

Dr. Daniel Normolle has expertise in biostatistics and serves as an Associate Professor in the Department of Biostatistics at the University of Pittsburgh School of Public Health. With a strong commitment to advancing the field, he plays a pivotal role in shaping the next generation of biostatisticians through his teaching and mentorship. Dr. Normolle's academic journey and professional endeavors are marked by a dedication to integrating statistical methodologies with public health research. In addition to his academic responsibilities, Dr. Normolle is the Director of the Biostatistics Facility at the UPMC Hillman Cancer Center. In this capacity, he collaborates with a multidisciplinary team to provide statistical support for cancer research, ensuring that studies are designed and analyzed with precision and rigor. His work at the cancer center underscores his commitment to applying biostatistical principles to real-world health challenges, contributing to the development of innovative solutions in cancer treatment and prevention. Dr. Normolle's contributions to both academia and applied research highlight his integral role in the intersection of biostatistics and public health.

Research Interests

Biostatistics public health research cancer research statistical methodologies

Publications

1 - Epigenetic Priming Using Decitabine Followed By Cytarabine As an Induction Regimen in Older Patients with Newly Diagnosed Acute Myeloid Leukemia,Blood

Annie Im , Jing-Zhou Hou , Anastasios Raptis , Mounzer Agha , Rafic Farah , Robert L. Redner , Alison R. Sehgal , Kathleen A. Dorritie , Ann Welsh , Daniel E. Johnson , Daniel Normolle , Michael Boyiadzis ,

, 2265-2265, 2014-12-06

2 - Phase 2 Study of Epigenetic Priming Using Decitabine Followed By Cytarabine As an Induction Regimen in Older Patients with Newly Diagnosed Acute Myeloid Leukemia,Blood

Annie Im , Mounzer Agha , Anastasios Raptis , Jing-Zhou Hou , Rafic Farah , Seah H. Lim , Robert Redner , Alison R. Sehgal , Kathleen A. Dorritie , Ann Welsh , Linda Fukas , Christine Tripoli , Daniel Normolle , Daniel E Johnson , Michael Boyiadzis ,

, 3739-3739, 2015-12-03

3 - Lenalidomide and Dexamethasone Alone Is Equivalent To Lenalidomide and Dexamethasone With Autologous Stem Cell Transplant In Newly Diagnosed Multiple Myeloma: Interim Study Results Of a Randomized Trial,Blood

Jordan M. Schecter , Kristen Kipps , Amy O'Sullivan , Kent A. Griffith , Daniel Normolle , Markus Mapara , Robert Redner , Suzanne Lentzsch ,

, 3180-3180, 2013-11-15

4 - Higher Number of Cycles of Cytarabine Consolidation Improves Outcomes in Elderly AML Patients,Blood

Asha Ricciuti , Mounzer Agha , Anastasios Raptis , Jing-Zhou Hou , Rafic Farah , Robert L. Redner , Alison R. Sehgal , Kathleen A. Dorritie , James M. Rossetti , Yongli Shuai , Daniel Normolle , Rahim Remtulla , Shawn Tahata , Michael Boyiadzis , Annie Im ,

, 4000-4000, 2018-11-29

5 - Validation of Kantarjian (2010) Model for Intensive Chemotherapy in Older Adults with Acute Myeloid Leukemia,Blood

Shawn Tahata , Annie Im , Michael Boyiadzis , Daniel Normolle ,

, 5258-5258, 2018-11-29

6 - Abstract 894: Sulforaphane as a chemopreventive agent against oral carcinogenesis,Cancer Research

Julie E. Bauman , Yan Zang , Malabika Sen , Daniel P. Normolle , Thomas W. Kensler , Sumita Trivedi , Patricia A. Egner , Siddharth H. Sheth , Jennifer R. Grandis , Daniel E. Johnson ,

, 894-894, 2015-08-01

7 - A randomized phase II study evaluating concurrent or sequential fixed-dose immune therapy in combination with cisplatin and intensity-modulated radiotherapy in intermediate- or high-risk, previously untreated, locally advanced head and neck cancer (LA SCCHN).,Journal of Clinical Oncology

David Anthony Clump , Dan Paul Zandberg , Heath Devin Skinner , James Ohr , Moon Jung Fenton , Daniel Paul Normolle , Jonathan Jay Beitler , Julie E. Bauman , Robert L. Ferris ,

, 6007-6007, 2022-06-01

8 - NCI 9938: Phase I clinical trial of ATR inhibitor berzosertib (M6620, VX-970) in combination with irinotecan in patients with advanced solid tumors.,Journal of Clinical Oncology

Liza C Villaruz , Karen Kelly , Saiama Naheed Waqar , Elizabeth J. Davis , Geoffrey Shapiro , Patricia LoRusso , Elizabeth Claire Dees , Daniel Paul Normolle , John C. Rhee , Edward Chu , Steven Gore , Jan Hendrik Beumer ,

, 3012-3012, 2022-06-01

9 - Abstract 5563: Dietary phenethyl isothiocyanate administration inhibits prostate cancer development in transgenic adenocarcinoma of mouse prostate mice in association with induction of autophagy and suppression of plasma clusterin,Cancer Research

Anna A. Powolny , Ajay Bommareddy , Eun-Ryeong Hahm , Daniel Normolle , Jan H. Beumer , Joel B. Nelson , Shivendra V. Singh ,

, 5563-5563, 2011-04-01

10 - Dietary fibre to reduce colon cancer risk in Alaska Native people: the Alaska FIRST randomised clinical trial protocol,BMJ Open

Kathryn R Koller , Annette Wilson , Daniel P Normolle , Jeremy K Nicholson , Jia V Li , James Kinross , Flora R Lee , Christie A Flanagan , Zoe T Merculieff , Priya Iyer , Daniela L Lammers , Timothy K Thomas , Stephen J D O"Keefe ,

, e047162, 2021-08-01

11 - Whole-liver irradiation with hepatic arterial floxuridine/leucovorin/streptozotocin followed by hepatic arterial floxuridine/leucovorin and chemo-embolization with mitomycin C for patients with metastatic neuroendocrine tumors.,Journal of Clinical Oncology

Mark Shilkrut , Sheela Hanasoge , Daniel Paul Normolle , Edgar Ben-Josef , William D. Ensminger , Theodore Steven Lawrence , Mary Uan-Sian Feng ,

, 339-339, 2012-02-01

12 - Phase I Trial of Dose-escalated Whole Liver Irradiation With Hepatic Arterial Fluorodeoxyuridine/Leucovorin and Streptozotocin Followed by Fluorodeoxyuridine/Leucovorin and Chemoembolization for Patients With Neuroendocrine Hepatic Metastases,American Journal of Clinical Oncology

Mark Shilkrut , Eli Sapir , Sheela Hanasoge , Matthew J. Schipper , Daniel P. Normolle , Edgar Ben-Josef , William Ensminger , Theodore S. Lawrence , Mary Feng ,

, 326-331, 2018-04-01

13 - Recurrence and Survival Outcomes After Anatomic Segmentectomy Versus Lobectomy for Clinical Stage I Non–Small-Cell Lung Cancer: A Propensity-Matched Analysis,Journal of Clinical Oncology

Rodney J. Landreneau , Daniel P. Normolle , Neil A. Christie , Omar Awais , Joseph J. Wizorek , Ghulam Abbas , Arjun Pennathur , Manisha Shende , Benny Weksler , James D. Luketich , Matthew J. Schuchert ,

, 2449-2455, 2014-08-10

14 - A phase 2 trial of regorafenib as a single agent in patients with chemotherapy‐refractory, advanced, and metastatic biliary tract adenocarcinoma,Cancer

Weijing Sun , Anuj Patel , Daniel Normolle , Krishna Patel , James Ohr , James J. Lee , Nathan Bahary , Edward Chu , Natalie Streeter , Summer Drummond ,

, 902-909, 2018-12-18

15 - Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck,Journal for ImmunoTherapy of Cancer

Dan P Zandberg , Ashley V Menk , Maria Velez , Daniel Normolle , Kristin DePeaux , Angen Liu , Robert L Ferris , Greg M Delgoffe ,

, e002088, 2021-05-01

16 - Rapid rational drug targeting of Merkel cell polyomavirus (MCV)-positive Merkel cell carcinoma (MCC) using the survivin inhibitor YM155.,Journal of Clinical Oncology

Reety Arora , Masahiro Shuda , Anna Guastafierro , Tuna Toptan , Yanis Tolstov , Daniel Paul Normolle , Laura Vollmer , Andreas Vogt , Alexander Domling , Jeffrey Brodsky , Yuan Chang , Patrick S. Moore ,

, 8577-8577, 2012-05-20

Share Daniel's Profile